Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma

Alessia Castellino; Aung M Tun; Yucai Wang; Thomas M Habermann; Rebecca L King; Kay M Ristow; James R Cerhan; David J Inwards; Jonas Paludo; Stephen M Ansell; Thomas E Witzig; Grzegorz S Nowakowski

doi:10.1038/s41408-020-00394-z

Back

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma

Journal article

Open access

Peer reviewed

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma

Alessia Castellino, Aung M Tun, Yucai Wang, Thomas M Habermann, Rebecca L King, Kay M Ristow, James R Cerhan, David J Inwards, Jonas Paludo, Stephen M Ansell, …

Blood cancer journal (New York), Vol.11(1), pp.8-8

01/07/2021

DOI: 10.1038/s41408-020-00394-z

PMCID: PMC7791108

PMID: 33414416

Files and links (1)

url

https://doi.org/10.1038/s41408-020-00394-zView

Published (Version of record) Open Access

Abstract

Primary gastrointestinal (GI) mantle cell lymphoma (MCL) is rare and the optimal management is unknown. We reviewed 800 newly diagnosed MCL cases and found 22 primary (2.8%) and 79 (9.9%) secondary GI MCL cases. Age, sex, and performance status were similar between primary and secondary cases. Secondary cases had more elevations in lactate dehydrogenase (28% vs 0%, P = 0.03) and a trend for a higher MCL international prognostic index (P = 0.07). Observation or local therapy was more common for primary GI MCL (29% vs 8%, P < 0.01), and autologous stem-cell transplant was more common for secondary GI MCL (35% vs 14%, P < 0.05). The median follow-up was 85 months. Primary and secondary GI MCL had similar 5-year progression-free survival (PFS) (30% vs 28%, P = 0.59) and overall survival (OS) (65% vs 66%, P = 0.83). The extent of GI involvement in primary GI MCL affected treatment selection but not outcome, with a 5-year PFS of 43% vs 14% vs 31% (P = 0.48) and OS of 57% vs 71% vs 69% (P = 0.54) in cases with single lesion vs multiple lesions in 1 organ vs multiple lesions in ≥2 organs. Less aggressive frontline treatment for primary GI MCL is reasonable. It is unknown whether more aggressive treatment can result in improved outcomes.

Details

Title: Subtitle: Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
Creators: Alessia Castellino - Division of Hematology, Mayo Clinic, Rochester, USA
Aung M Tun - University of Kansas
Yucai Wang - Division of Hematology, Mayo Clinic, Rochester, USA,
Thomas M Habermann - Mayo Clinic
Rebecca L King - Mayo Clinic
Kay M Ristow - Mayo Clinic
James R Cerhan - Mayo Clinic
David J Inwards - Mayo Clinic
Jonas Paludo - Division of Hematology, Mayo Clinic, Rochester, USA,
Stephen M Ansell - Mayo Clinic
Thomas E Witzig - Mayo Clinic
Grzegorz S Nowakowski - Mayo Clinic
Resource Type: Journal article
Publication Details: Blood cancer journal (New York), Vol.11(1), pp.8-8
DOI: 10.1038/s41408-020-00394-z
PMID: 33414416
PMCID: PMC7791108
NLM abbreviation: Blood Cancer J
ISSN: 2044-5385
eISSN: 2044-5385
Grant note: P30 CA086862 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
Language: English
Date published: 01/07/2021
Academic Unit: Epidemiology
Record Identifier: 9984368222402771

Metrics

6 Record Views

12 Times Cited - Web of Science

See more details